


pantoprazole
Somac® first

VISIT THE NYCOMED EXHIBIT TO VIEW LIVE PROCEDURES CONDUCTED ON AN ERLANGER ENDO TRAINER MODEL



**12.30 PM EACH DAY
- EXHIBIT 19 -**



PBS Information: Restricted Benefit.

Gastro-oesophageal reflux disease; initial treatment of peptic ulcer;
Zollinger-Ellison syndrome; scleroderma oesophagus.

Before prescribing, please review Approved Product Information. Full PI available from Nycomed Pty Ltd, ABN 71095 610 870, 2-4 Lyonpark Road, North Ryde NSW 2113. SOMAC® (pantoprazole) INDICATIONS: Duodenal and gastric ulcers; gastro-oesophageal reflux disease (GORD), including symptomatic GORD and reflux oesophagitis; gastrointestinal lesions refractory to H2 blockers; Zollinger-Ellison Syndrome; maintenance of healed reflux oesophagitis; eradication of *H. pylori* in peptic ulcer (combination therapy); prevention of gastroduodenal lesions and dyspeptic symptoms associated with non-selective NSAIDs in increased risk patients with a need for continuous NSAID treatment. CONTRAINDICATIONS: Hypersensitivity to ingredients; cirrhosis; severe liver disease. Combination therapy: Hypersensitivity to antibiotics; moderate to severe hepatic or renal dysfunction, atazanavir therapy#. PRECAUTIONS: If suspected gastric ulcer or reflux oesophagitis, exclude malignancy; rare cases of Vitamin B12 deficiency reported; monitoring for long-term use; investigation if non-responsive symptomatic GORD; pregnancy; lactation; children; monitoring for patients on coumarin anticoagulants; drugs with pH dependent bioavailability, including atazanavir#. ADVERSE EVENTS: Most commonly reported: Fatigue, asthenia, sweating, headache, diarrhoea, severe eructation, constipation, flatulence, dry mouth, upper abdominal pain, metallic taste, psychiatric disorders#; others, see full PI. DOSAGE AND ADMINISTRATION: Monotherapy: 20-40 mg once daily depending on indication (may be increased for Zollinger-Ellison Syndrome or reflux oesophagitis), see full PI. Combination therapy: 40 mg twice daily. Reduced initial dose with mild liver disease. #Please note changes in Product Information. 1. Sachs G. *Pharmacotherapy* 2003; 23 (Suppl): 68S-73S. 2. Shin JM *et al. Gastroenterology* 2002; 123: 1588-1597. 3. Somac Product Information, November 2006. 4. Sachs G *et al. Drugs Today* 2004; 40 (Suppl A): 9-14. 5. Sachs G *et al. Drugs Today* 2003; 39 (Suppl A): 11-14. 6. Shin JM *et al. Biochem Pharmacol* 2004; 68: 2117-2127. 7. Richter JE *et al. Am J Gastroenterol* 2000; 95: 3071-3080. 8. Richter JE *et al. Aliment Pharmacol Ther* 2004; 20: 567-575. 9. Bardhan KD *et al. Dig Liver Dis* 2005; 37: 10-22. 10. *Schedule of Pharmaceutical Benefits*. Commonwealth Department of Health and Ageing, February 2007. ©Registered Trademark 10/07 ANT-SOM002



pantoprazole
Somac® lasts 1-9

